Skip to main content

Fiscal Wizard · Single-issue tearsheet

INVA / Jun 22, 2026 Run #7597

INVA

Innoviva, Inc.

Innoviva, Inc. operates as a biopharmaceutical company in the United States and internationally. Its royalty portfolio includes RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol, and an inhaled corticosteroid, and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist, umeclidinium bromide, and ABA, VI. The company also markets GIAPREZA for increasing blood pressure in adults with septic or other distributive shock; XACDURO, a co-packaged for intravenous use for the treatment of hospital-acquired and ventilator-associated bacterial pneumonia caused by Acinetobacter; XERAVA for the treatment of complicated intra-abdominal infections in adults; ZEVTERA an advanced-generation cephalosporin antibiotic for the treatment of staphylococcus aureus bacteremia, as well as with right-sided endocarditis, acute bacterial skin and skin structure infections, and community-acquired bacterial pneumonia; NUZOLVENCE for the treatment of uncomplicated urogenital gonorrhea in adults and adolescents. In addition, the company develops bacteriophages with potential use in a range of infectious and other serious diseases. It has a strategic partnership with Sarissa Capital Management LP; and LABA Collaboration Agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.

Composite verdict

A 93.5 / 100
Bullish setup · Reversal 10 drivers · 3 gates blocking
  • Vortex Signal
  • Multi Top/Bottom
  • Sushi Roll
Consider long call target Δ ~0.70 · ~35 DTE Bullish setup, Grade A → ITM call target

Industry rank 2nd of 598 in Biotechnology

rescore-sweep
Technical synthesisRegime: range
Bull 100%Evidence: High · 22 signals0% Bear
Momentum Bullish 88Mean-reversion Neutral 56

No notable composite patterns — the signals don't cluster into a named setup right now.

Where value comes fromMargin of safety -17%
Asset value $15.89Earnings power value $24.42Price $22.49

The discount is mostly unpriced earnings power: price ($22.49) sits between asset value ($15.89) and no-growth earnings power value ($24.42).

Fundamentals Strong

87.2 / 100

Score-bearing fundamentals shown here exclude gate-only risk checks. · 35 metrics shown.

Strongest
Weakest
Days Sales Outstanding 100
Cash Conversion Cycle 0
EPS Growth (YoY) 100
PEG 1
Earnings Yield 100
Inventory Turnover 1

Technicals Bullish

99.8 / 100

Bullish setup leads (Vortex Signal, Multi Top/Bottom, Sushi Roll); bears gated by guards. · 43 signals shown.

Strongest
Weakest
Vortex Signal 88
Sushi Roll 87
Multi Top/Bottom 84

Risk Gates

3 blocking 5 caution

3 guards active, 19 signals gated.

ADX Trend Weakness Blocking

Weak trend strength blocks trend-following signals in either direction.

MA Crossover Blocking

Blocks counter-regime signals only when the MA crossover agrees with the long-term regime.

Regime Filter Blocking

Blocks signals that oppose the long-term moving-average regime.

Cash Ratio Caution

Visual cash-cushion flag — does not mute signals.

Breakdown

Look under the hood

Empty pane

Pick a category, above, to crack it open.

Every chip in either subscore card drills into the metrics or signals that fed it — including the formula, the threshold band, and what the current reading means for INVA.